<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ixico Plc — News on 6ix</title>
<link>https://6ix.com/company/ixico-plc</link>
<description>Latest news and press releases for Ixico Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 22 May 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ixico-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e76b78dffbe2df128ffe.webp</url>
<title>Ixico Plc</title>
<link>https://6ix.com/company/ixico-plc</link>
</image>
<item>
<title>Company presentation at Mello 2026</title>
<link>https://6ix.com/company/ixico-plc/news/company-presentation-at-mello-2026</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/company-presentation-at-mello-2026</guid>
<pubDate>Fri, 22 May 2026 06:00:00 GMT</pubDate>
<description>IXICO plc announced that its CEO will present at the Mello2026 investor event on June 3rd, 2026, to discuss recent positive financial results from May 19th, 2026, the company's growth trajectory, and future strategy. The presentation will highlight IXICO's role as a leader in neuroscience imaging and biomarker analytics, utilizing its AI-driven platform to advance drug and diagnostics development for neurological disorders.
Disclaimer*</description>
</item>
<item>
<title>Contract win and contract extension</title>
<link>https://6ix.com/company/ixico-plc/news/contract-win-and-contract-extension</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/contract-win-and-contract-extension</guid>
<pubDate>Thu, 21 May 2026 06:00:00 GMT</pubDate>
<description>IXICO plc has secured new business and contract extensions valued at £1.3 million over two years, bolstering its position in neurological disorder research. The company will provide amyloid PET imaging analytics to validate a new Alzheimer's Disease blood-based biomarker test, aiming for FDA clearance, and has extended a Phase 2 Huntington's Disease clinical trial contract by adding three new analysis methodologies. These developments align with IXICO's growth strategy, deepening its impact in A</description>
</item>
<item>
<title>Interim results for six months ending 31/03/2026</title>
<link>https://6ix.com/company/ixico-plc/news/interim-results-for-six-months-ending-31032026</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/interim-results-for-six-months-ending-31032026</guid>
<pubDate>Tue, 19 May 2026 06:00:00 GMT</pubDate>
<description>IXICO plc reported a 23% increase in revenue to £3.9 million for the six months ending March 31, 2026, compared to £3.2 million in the prior year, with a gross margin rising to 53% from 50%. The company's order book grew by 38% to £18.1 million, and the EBITDA loss narrowed to £0.5 million from £0.7 million. Following the period, IXICO completed a £10 million capital raise to support its TechBio strategy, aiming to integrate its AI-driven platform with other industry providers. The company expec</description>
</item>
<item>
<title>IXICO Updates AI Neuroimaging Platform</title>
<link>https://6ix.com/company/ixico-plc/news/ixico-updates-ai-neuroimaging-platform</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/ixico-updates-ai-neuroimaging-platform</guid>
<pubDate>Tue, 12 May 2026 06:00:00 GMT</pubDate>
<description>IXICO plc has released version 10 of its AI-driven neuroimaging platform, IXI™, which enhances data processing speed and volume, improves image reading precision, and integrates new tools for remote access and data quality. This latest generation of IXI™ supports IXICO's TechBio strategy by enabling external organizations to access the technology through licensing and partnering models, aiming to expand the company's addressable market and assist biopharmaceutical companies in making earlier, mo</description>
</item>
<item>
<title>Result of GM and Update on Issue of Equity</title>
<link>https://6ix.com/company/ixico-plc/news/result-of-gm-and-update-on-issue-of-equity</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/result-of-gm-and-update-on-issue-of-equity</guid>
<pubDate>Thu, 16 Apr 2026 11:01:00 GMT</pubDate>
<description>IXICO plc announced that all resolutions were passed at its General Meeting concerning the Placings, Subscription, and Retail Offer, authorizing directors to allot relevant securities for cash up to an aggregate nominal amount of £1,312,500 for the fundraising and an additional £746,395 under a general authority, with Resolution 1 passing with 78.67% of votes for. The company is still awaiting Advanced Assurance from HM Revenue & Customs for the equity issue, which is a condition for the First a</description>
</item>
<item>
<title>Placings and Subscription</title>
<link>https://6ix.com/company/ixico-plc/news/placings-and-subscription</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/placings-and-subscription</guid>
<pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
<description>IXICO plc announced a proposed fundraising of up to £10.5 million, comprising a £2.8 million First Placing, a £0.1 million Subscription by directors, a £7.1 million Second Placing conditional on tax legislation changes, and a £0.5 million Retail Offer. The funds will be used to develop the IXI™ Platform, invest in sales staff, and pursue FDA approval for the product as a medical device. The issue price of 8 pence per share represents a 1.6% premium to the previous day's closing price. The compan</description>
</item>
<item>
<title>Collaboration with Medidata</title>
<link>https://6ix.com/company/ixico-plc/news/collaboration-with-medidata</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/collaboration-with-medidata</guid>
<pubDate>Thu, 26 Mar 2026 07:00:00 GMT</pubDate>
<description>IXICO plc has announced a technology collaboration with Medidata, a Dassault Systèmes brand, to create an advanced neuroimaging clinical trials platform. This partnership will integrate IXICO's IXI™ Platform with Medidata's solutions, offering a unified user experience for biopharma companies to manage and analyze complex neuroimaging data within a secure, regulatory-compliant system. The collaboration is expected to expand IXICO's market reach and provide opportunities for technological co-deve</description>
</item>
<item>
<title>Validation of Neuroimaging Technology Platform</title>
<link>https://6ix.com/company/ixico-plc/news/validation-of-neuroimaging-technology-platform</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/validation-of-neuroimaging-technology-platform</guid>
<pubDate>Thu, 26 Feb 2026 07:00:00 GMT</pubDate>
<description>IXICO plc has presented new data validating its IXI™ Platform's automated neuroimaging capabilities, demonstrating that its automated measurement of brain volume loss on MRI matches or exceeds the performance of traditional semi-manual methods like the Boundary Shift Integral (BSI). In a study with a US pharmaceutical partner, the IXI™ Platform proved most sensitive in detecting whole brain and caudate volume loss, offering a more cost-effective and scalable solution for clinical trials in neuro</description>
</item>
<item>
<title>Correction: c.£1.5 million Contract Extension</title>
<link>https://6ix.com/company/ixico-plc/news/correction-cpound15-million-contract-extension</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/correction-cpound15-million-contract-extension</guid>
<pubDate>Thu, 12 Feb 2026 08:48:00 GMT</pubDate>
<description>IXICO plc has announced a contract extension worth approximately £1.5 million in additional revenues over the next three years with a leading international pharmaceutical company, related to a Phase 2 clinical trial for Huntington's Disease. This extension highlights the continued progress of the trial and the value of IXICO's AI-driven platform and neuroscience imaging expertise in drug development.
Disclaimer*</description>
</item>
<item>
<title>c.£1.5 million Contract Extension</title>
<link>https://6ix.com/company/ixico-plc/news/cpound15-million-contract-extension</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/cpound15-million-contract-extension</guid>
<pubDate>Thu, 12 Feb 2026 07:00:00 GMT</pubDate>
<description>IXICO plc has announced a contract extension worth approximately £1.5 million in additional revenue over the next three years, stemming from the continued progress of a Phase 2 clinical trial in Huntington's Disease with a major international pharmaceutical company. This extension, secured within two months of other new revenue totaling over £2.7 million from two existing clients, highlights the value of IXICO's AI-driven platform and neuroscience expertise in advancing drug development for neur</description>
</item>
<item>
<title>Appointment of Chief Commercial Officer</title>
<link>https://6ix.com/company/ixico-plc/news/appointment-of-chief-commercial-officer-5</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/appointment-of-chief-commercial-officer-5</guid>
<pubDate>Thu, 05 Feb 2026 07:00:00 GMT</pubDate>
<description>IXICO plc has appointed Tanya Voloshen as Chief Commercial Officer, a new senior leadership role based in Boston, USA, aimed at accelerating business development and expanding the company's US presence. Voloshen brings extensive commercial and executive leadership experience from the neuroimaging market, having previously held senior roles at Perceptive Inc., Clario, QMENTA, and ConcertAI, with early career experience at Johnson & Johnson and Sanofi. This strategic hire underscores IXICO's commi</description>
</item>
<item>
<title>Results of AGM</title>
<link>https://6ix.com/company/ixico-plc/news/results-of-agm-54</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/results-of-agm-54</guid>
<pubDate>Fri, 23 Jan 2026 17:05:00 GMT</pubDate>
<description>IXICO plc announced that all resolutions presented at its Annual General Meeting were passed with overwhelming support, including the re-election of directors Bram Goorden, Grant Nash, Mark Warne, Dr Dipti Amin, and Kate Rogers, with over 99.99% of votes cast in favour for each. The re-appointment of auditors Moore Kingston Smith and the allotment of securities also received near unanimous approval, with 100% of votes for the auditors and 100% for the allotment of securities. The resolution to d</description>
</item>
<item>
<title>Share option award</title>
<link>https://6ix.com/company/ixico-plc/news/share-option-award</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/share-option-award</guid>
<pubDate>Tue, 09 Dec 2025 07:05:00 GMT</pubDate>
<description>IXICO plc has issued 1,400,000 share options to members of its broader leadership team, with vesting tied to retention and three-year annual revenue growth, and an exercise price of £0.01, subject to a hold period until the third anniversary of the award.
Disclaimer*</description>
</item>
<item>
<title>Financial Results for year ended 30 September 2025</title>
<link>https://6ix.com/company/ixico-plc/news/financial-results-for-year-ended-30-september-2025</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/financial-results-for-year-ended-30-september-2025</guid>
<pubDate>Tue, 09 Dec 2025 07:00:00 GMT</pubDate>
<description>IXICO plc reported a strong financial performance for the year ended 30 September 2025, with revenue growing 13% to £6.5 million and EBITDA losses reducing by 20% to £1.3 million. The company's order book increased by 27% to £17.7 million by the end of November 2025, reflecting accelerated contract wins. The Group ended the year with a debt-free cash balance of £3.5 million and net assets of £11.7 million. The company also announced its 2026 Annual General Meeting will be held on 23 January 2026</description>
</item>
<item>
<title>Operational Update</title>
<link>https://6ix.com/company/ixico-plc/news/operational-update-56</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/operational-update-56</guid>
<pubDate>Mon, 01 Dec 2025 07:00:00 GMT</pubDate>
<description>IXICO plc has appointed two prominent global experts, Professor Michael Weiner and Professor Joanna Wardlaw, to its Scientific Advisory Board, bolstering its strategy in Alzheimer's Disease and vascular biomarker development. These appointments, announced at the CTAD conference, align with IXICO's focus on AI-driven drug development for neurological disorders, particularly in identifying and measuring vascular abnormalities which are common contributors to neurodegenerative diseases. The company</description>
</item>
<item>
<title>Notice of 2025 Full Year Results and IMC</title>
<link>https://6ix.com/company/ixico-plc/news/notice-of-2025-full-year-results-and-imc</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/notice-of-2025-full-year-results-and-imc</guid>
<pubDate>Thu, 27 Nov 2025 07:00:00 GMT</pubDate>
<description>IXICO plc will release its Full Year Results for the year ending 30 September 2025 on Tuesday, 09 December 2025, and will host a live investor presentation on the Investor Meet Company platform at 16:30 GMT on the same day. Existing and potential shareholders can submit questions prior to the event by 09:00 GMT on 08 December 2025 or during the presentation. A recording of the results presentation will be made available on the company's website.
Disclaimer*</description>
</item>
<item>
<title>Clinical Trial Contract Win</title>
<link>https://6ix.com/company/ixico-plc/news/clinical-trial-contract-win</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/clinical-trial-contract-win</guid>
<pubDate>Mon, 17 Nov 2025 07:00:00 GMT</pubDate>
<description>IXICO plc has secured a significant new commercial contract valued at over £3.5 million over four years with a global pharmaceutical company for imaging services in a worldwide Phase 3 clinical trial for Huntington's Disease, demonstrating continued positive commercial momentum and reinforcing its position in neuroscience precision medicine.
Disclaimer*</description>
</item>
<item>
<title>Capital Markets Day Presentation and Video</title>
<link>https://6ix.com/company/ixico-plc/news/capital-markets-day-presentation-and-video</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/capital-markets-day-presentation-and-video</guid>
<pubDate>Mon, 03 Nov 2025 14:30:00 GMT</pubDate>
<description>IXICO plc announced that a recording of its Capital Markets Day, held on October 30, 2025, is available on the company's website. According to the CEO, IXICO is on track to continue delivering double digit topline growth and achieve profitability in the medium term. The company's future success is expected to be driven by the evolution and innovation of its AI-tech platform, in partnership with biopharma, data, and AI players within neurological precision medicine.
Disclaimer*</description>
</item>
<item>
<title>Trading Update</title>
<link>https://6ix.com/company/ixico-plc/news/trading-update-293</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/trading-update-293</guid>
<pubDate>Thu, 16 Oct 2025 06:00:00 GMT</pubDate>
<description>IXICO plc reported a trading update for the year ended September 30, 2025, with revenues exceeding market expectations at £6.5 million, a 13% increase from £5.8 million in 2024. The year-end order book stood at £13.8 million, compared to £15.3 million the previous year, with a second-half increase from £13.1 million driven by £4.2 million in new contracts and extensions. Since the end of September, the company has secured £0.9 million in new contracts and extensions. Year-end cash increased to £</description>
</item>
<item>
<title>New contract win and contract extension</title>
<link>https://6ix.com/company/ixico-plc/news/new-contract-win-and-contract-extension</link>
<guid isPermaLink="true">https://6ix.com/company/ixico-plc/news/new-contract-win-and-contract-extension</guid>
<pubDate>Wed, 15 Oct 2025 06:00:00 GMT</pubDate>
<description>IXICO plc announced a new commercial contract and a contract extension with a combined value of approximately £1.2 million. The new contract, spanning under three years, involves assisting a leading global biopharma company in validating a diagnostic blood test for an undisclosed neurodegenerative disease, utilizing IXICO's platform for analysis. The contract extension adds activities to an existing Alzheimer's Disease clinical trial, reflecting a series of smaller scope additions with existing </description>
</item>
</channel>
</rss>